Page 12 - Sight Sciences News Today

Ocular Surgery News | The volume of minimally invasive glaucoma surgery has increased significantly in recent years, providing an alternative to traditional glaucoma surgeries.Data from various studies demonstrate that MIGS is associated with low risk for adverse events and has beneficial effects on visual field preservation, quality of life and cost-effectiveness among patients with mild to moderate glaucoma.

Canaloplasty and trabeculotomy performed with the Omni surgical system provided patients with glaucoma with sustained IOP control over 2 years, according to a study published in Clinical Ophthalmology.

Ophthalmic lasers are devices that allow precise treatment for a range of eye problems with little risk of infection. Many laser procedures are relatively

Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 monthsSustained and... | May 23, 2023

Sight Sciences (NASDAQ:SGHT – Get Rating) and NEXGEL (NASDAQ:NXGL – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Institutional & Insider Ownership 50.2% of Sight Sciences shares are […]

Blogs | | Thar she blows! My name is Dr. Ahab, and my personal Moby Dick has finally surfaced off the port bow. After many, many months in a purgatory brought on by abysmal care and feeding provided by its prior owner, AzaSite is now available.

Jackson Square Partners LLC lifted its stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT – Get Rating) by 43.4% during the fourth quarter, Holdings Channel reports. The firm owned 1,209,704 shares of the company’s stock after purchasing an additional 366,093 shares during the quarter. Jackson Square Partners LLC’s holdings in Sight Sciences were worth $14,770,000 […]

SAN DIEGO — Surgeons should optimize their treatment of dysphotopsias based on each patient’s natural ability for neuroadaptation, according to a speaker here.

Operator: Good day and thank you for standing by. Welcome to the Sight Sciences First Quarter 2023 Earnings Results Call. At this time, all participants are in a listen-only mode.

® Delivering the Power of Sight™ Investor Presentation May 2023 ... | May 8, 2023